Vitamin Shoppe Inc (VSI) Expected to Post Quarterly Sales of $262.27 Million
Equities analysts forecast that Vitamin Shoppe Inc (NYSE:VSI) will announce sales of $262.27 million for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Vitamin Shoppe’s earnings. The highest sales estimate is $262.89 million and the lowest is $261.64 million. Vitamin Shoppe reported sales of $304.87 million during the same quarter last year, which suggests a negative year over year growth rate of 14%. The company is expected to announce its next earnings results before the market opens on Tuesday, February 27th.
According to Zacks, analysts expect that Vitamin Shoppe will report full year sales of $262.27 million for the current fiscal year, with estimates ranging from $1.17 billion to $1.19 billion. For the next fiscal year, analysts forecast that the business will report sales of $1.16 billion per share, with estimates ranging from $1.14 billion to $1.17 billion. Zacks’ sales calculations are an average based on a survey of research analysts that cover Vitamin Shoppe.
Several analysts have commented on the stock. Barclays lowered their target price on shares of Vitamin Shoppe from $6.00 to $3.00 and set an “equal weight” rating for the company in a research note on Thursday, November 9th. ValuEngine cut shares of Vitamin Shoppe from a “buy” rating to a “hold” rating in a research note on Sunday, December 31st. Morgan Stanley lowered their target price on shares of Vitamin Shoppe from $7.50 to $4.00 and set an “equal weight” rating for the company in a research note on Thursday, November 9th. Finally, Zacks Investment Research raised shares of Vitamin Shoppe from a “strong sell” rating to a “hold” rating in a research note on Sunday, January 21st. Three investment analysts have rated the stock with a sell rating and six have issued a hold rating to the stock. Vitamin Shoppe presently has a consensus rating of “Hold” and an average target price of $5.00.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Landscape Capital Management L.L.C. grew its stake in shares of Vitamin Shoppe by 341.5% during the 4th quarter. Landscape Capital Management L.L.C. now owns 474,790 shares of the specialty retailer’s stock valued at $2,089,000 after buying an additional 367,240 shares during the period. Lazard Asset Management LLC purchased a new stake in Vitamin Shoppe during the 4th quarter worth $115,000. OppenheimerFunds Inc. boosted its position in Vitamin Shoppe by 27.8% during the 4th quarter. OppenheimerFunds Inc. now owns 194,339 shares of the specialty retailer’s stock worth $855,000 after purchasing an additional 42,269 shares during the period. BlackRock Inc. boosted its position in Vitamin Shoppe by 7.0% during the 4th quarter. BlackRock Inc. now owns 3,125,360 shares of the specialty retailer’s stock worth $13,752,000 after purchasing an additional 203,710 shares during the period. Finally, Pinebridge Investments L.P. boosted its position in Vitamin Shoppe by 28.3% during the 4th quarter. Pinebridge Investments L.P. now owns 63,860 shares of the specialty retailer’s stock worth $281,000 after purchasing an additional 14,079 shares during the period. 99.86% of the stock is owned by institutional investors.
Shares of Vitamin Shoppe (NYSE VSI) opened at $3.85 on Wednesday. The company has a market cap of $93.51, a P/E ratio of -0.36 and a beta of 0.59. The company has a quick ratio of 0.32, a current ratio of 2.07 and a debt-to-equity ratio of 0.59. Vitamin Shoppe has a 12 month low of $2.95 and a 12 month high of $23.25.
About Vitamin Shoppe
Vitamin Shoppe, Inc (VSI) is a multi-channel specialty retailer and contract manufacturer of vitamins, minerals, herbs, specialty supplements, sports nutrition, and other health and wellness products. The Company operates through three segments: retail, direct and manufacturing. The retail segment includes Vitamin Shoppe, Super Supplements and Vitapath retail store formats.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vitamin Shoppe Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitamin Shoppe and related companies with MarketBeat.com's FREE daily email newsletter.